Drugs / KC1036
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04387916 | Sep 2020 → Oct 2025 overdue | cancer | Beijing Konruns Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05260385 | Jan 2022 → Oct 2025 overdue | digestive system neoplasm | Beijing Konruns Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07481058 | Dec 2025 → Dec 2027 expected | esophageal squamous cell carcinoma | Beijing Konruns Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06564272 | Sep 2024 → Apr 2027 expected | Ewing sarcoma | Beijing Konruns Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05683886 | Feb 2023 → Feb 2025 overdue | thymus neoplasm | Beijing Konruns Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06194734 | Feb 2024 → Dec 2026 expected | esophageal squamous cell carcinoma | Beijing Konruns Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05265338 | Mar 2022 | — | Beijing Konruns Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KC1036 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05683886 ↗ |
| Route | Oral | “In the subsequent treatment cycles, KC1036 are given orally once daily, 21 days as a cycle.” NCT04387916 ↗ |